Identification of a Predictive Genomic Biomarker for Prostate-directed Therapy in Synchronous Low-volume Metastatic Castration-sensitive Prostate Cancer.

ABSTRACT:

Background

Standard of care management for synchronous metastatic castration-sensitive prostate cancer (mCSPC) includes androgen deprivation therapy with a second-generation antiandrogen therapy and/or docetaxel. Recently, randomized data have demonstrated that prostate-directed therapy (PDT) is associated with an improvement in overall survival (OS) among patients with low-volume metastatic disease. Tumor genomics represents an additional dimension to define the clinical trajectory of patients with mCSPC.

Objective

To evaluate a high-risk (HiRi) genomic signature to predict the benefit from PDT.

Design, setting, and participants

We performed a single-institution retrospective review of men with synchronous low-volume mCSPC who underwent DNA panel sequencing of their

SUBMITTER: Sutera P 

PROVIDER: S-EPMC10850431 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature